Abstract:Introduction: Nasopharyngeal carcinoma (NPC) responds well to radiotherapy but recurrence and metastasis are common. Currently, there is no widely used biomarker for accurately predicting the recurrence and metastasis of NPC. In this study, we aimed to evaluate the prognostic ability of Epstein-Barr virus (EBV) capsid antigen (VCA-IgA) kinetics by assessing the dynamic changes of VCA-IgA levels in the pre- and post-treatment plasma of patients with NPC and have proposed a prognostic model for clinical use. Methods: The clinical records of patients with NPC diagnosed at Sun Yat-sen University Cancer Center were retrieved and classified into a respondent (n = 83) or non-respondent (n = 25) cohort based on their response to antitumor therapy. Factors associated with the outcomes of the patients were assessed and incorporated in a nomogram. For internal validation, bootstrapping with 1000 resamples was used. The prediction accuracy and discriminative ability of the nomogram were investigated by calibration and concordance index (C-index) and plotted decision curves to assess the benefits of nomogram-assisted decisions in a clinical context. Results: Plasma VCA-IgA level of the non-respondent cohort at the 6th month after treatment was found significantly higher than the respondent cohort. Post-treatment VCA-IgA level, smoking, and distant metastases were identified as independent risk factors for disease-free survival (DFS), and were used to stratify patients with NPC into three risk groups. The median DFS of the low-, middle- and high-risk groups were 48.5, 35.0, and 15.5 months, respectively. The C-index of the nomogram was 0.848 (95% CI 0.769-0.926), demonstrating good clinical accuracy for predicting the DFS of patients with NPC. The decision curve showed that the nomogram in predicting DFS was better than VCA-IgA level, smoking, and distant metastases. Conclusion: The proposed VCA-IgA-based nomogram demonstrated a promising ability to predict the DFS of patients with NPC after antitumor therapy. It could be used as a clinical guidance to improve the therapeutic/surveillance strategies of these patients.

A Prognostic Model Predicts the Risk of Distant Metastasis and Death for Patients with Nasopharyngeal Carcinoma Based on Pre-Treatment Interleukin 6 and Clinical Stage.

As an Independent Unfavorable Prognostic Factor, IL-8 Promotes Metastasis of Nasopharyngeal Carcinoma Through Induction of Epithelial–mesenchymal Transition and Activation of AKT Signaling

A Prognostic Model Predicts the Risk of Distant Metastasis and Death for Patients with Nasopharyngeal Carcinoma Based on Pre-Treatment Serum C-reactive Protein and N-classification.

Prognostic Value of a Serum Panel of Inflammatory Factors in Non-Metastatic Nasopharyngeal Carcinoma Patients Undergoing Radical Radiotherapy with Adjuvant Chemotherapy

An immune-related prognostic model predicts neoplasm-immunity interactions for metastatic nasopharyngeal carcinoma

High Expression of NLR and SII in patients With Nasopharyngeal Carcinoma as Potential Prognostic Observations

Development and Validation of Immune Inflammation-Based Index for Predicting the Clinical Outcome in Patients with Nasopharyngeal Carcinoma

Staining of Interleukin-10 Predicts Clinical Outcome in Patients with Nasopharyngeal Carcinoma.

Systematic construction and external validation of an immune-related prognostic model for nasopharyngeal carcinoma

Establishment and Validation of a Novel MRI Radiomics Feature-Based Prognostic Model to Predict Distant Metastasis in Endemic Nasopharyngeal Carcinoma

[Development and validation of a multivariate risk model for distant metastasis of advanced nasopharyngeal carcinoma].

An Inflammatory Biomarker‐based Nomogram to Predict Prognosis of Patients with Nasopharyngeal Carcinoma: an Analysis of a Prospective Study

To Build a Prognostic Score Model Containing Indispensible Tumour Markers for Metastatic Nasopharyngeal Carcinoma in an Epidemic Area

A novel prognostic model predicts overall survival in patients with nasopharyngeal carcinoma based on clinical features and blood biomarkers

Associations of serum CD 62 P and IL-6 levels with nasopharyngeal carcinoma staging and prognosis

Prognostic Values of the Integrated Model Incorporating the Volume of Metastatic Regional Cervical Lymph Node and Pretreatment Serum Epstein–Barr Virus DNA Copy Number in Predicting Distant Metastasis in Patients with N1 Nasopharyngeal Carcinoma

A novel model for predicting prognosis and response to immunotherapy in nasopharyngeal carcinoma patients

Serum CCL2 and Serum TNF-α – Two New Biomarkers Predict Bone Invasion, Post-Treatment Distant Metastasis and Poor Overall Survival in Nasopharyngeal Carcinoma

Significance of Dynamic Changes of VCA-IgA Levels in Pre- and Post-treatment Plasma of Patients with Nasopharyngeal Carcinoma: Development of a Clinically-Oriented Model

Integrating iron metabolism-related gene signature to evaluate prognosis and immune infiltration in nasopharyngeal carcinoma

A Novel Prognostic Model Predicts Outcomes in Non-Metastatic Nasopharyngeal Carcinoma Based on Inflammation, Nutrition, and Coagulation Signature